Mochi Health vs Eden: Two Vertically-Integrated Compounders Compared
Mochi Health and Eden are both vertically-integrated compounded-GLP-1 specialists, but the comparison is not as symmetric as it looks. Both own (or operate) the compounding pharmacy that fills their prescriptions, which is structurally meaningful for sourcing transparency. The difference is the regulatory record: Eden's pharmacy has not been subject to state pharmacy enforcement, while Mochi's affiliated Aequita Pharmacy received a Washington State Notice of Immediate Jeopardy after substantiated whistleblower allegations of unlicensed-worker sterile compounding and improper cold-chain shipping.
Mochi Health
2.8Flat-rate compounded GLP-1 with a vertically-integrated pharmacy under active state and federal scrutiny
Eden
3.6Vertically-integrated GLP-1 telehealth with notable customer-service caveats
Reviewed by Designing Longevity Editorial·Last verified May 1, 2026
Bottom line
Eden for almost every reader. Both run vertical-integration stories, but Eden's holds up under regulatory scrutiny while Mochi's was directly contradicted by substantiated whistleblower allegations and subsequent WA State enforcement. Eden has its own counterweight (an active class-action investigation about possible undisclosed health-data sharing with ad-platform pixels), but a privacy investigation is meaningfully less severe than substantiated pharmacy-quality enforcement. Choose Mochi only if flat-rate dose-independent pricing is the binding constraint AND you have read the WA enforcement record on Aequita.
Side-by-side at a glance
Who wins for each use case
We pick a winner per criterion and explain the reasoning. Skip to whichever rows match how you'd actually use the platform.
Pharmacy-quality regulatory record
Winner: EdenEden's compounding pharmacy has no comparable state pharmacy enforcement on record. Mochi's affiliated Aequita Pharmacy received a Washington State Notice of Immediate Jeopardy after substantiated whistleblower allegations of unlicensed sterile compounding and improper cold-chain shipping; Aequita's listed owner signed an Agreed Order in July 2025 that did not contest the findings. This is the deciding signal in this comparison.
Vertical-integration credibility
Winner: EdenBoth providers market vertical integration. Eden's marketing holds up under regulatory scrutiny; Mochi's was directly contradicted by the WA State enforcement record. Vertical integration is only a quality signal if the operator actually runs the integrated pharmacy to standard.
Manufacturer lawsuit posture
Winner: EdenMochi has two active federal lawsuits (Eli Lilly April 2025 marketing, Novo Nordisk August 2025 marketing plus corporate-practice-of-medicine). Eden has no comparable open manufacturer litigation at capture date.
External review platform signal
Winner: Mochi HealthMochi has 4.4/5 across 15,600+ Trustpilot reviews with no fraud notice, materially more sample volume than Eden's roughly 3,000 reviews on Trustpilot. The volume gap is real and informative on the consumer-experience axis, with the caveat that Mochi's positive reviews are happening at a pharmacy with documented operational issues that few users would discover on their own.
Privacy posture
Winner: Mochi HealthEden has an active class-action investigation about possible undisclosed sharing of sensitive health data with ad-platform pixels (Meta, TikTok). Mochi has no comparable open privacy investigation at capture date. For privacy-sensitive users, this row tips Mochi, with the caveat that this is one of the only places Mochi's signal stack is meaningfully cleaner than Eden's.
Flat-rate dose-independent pricing
Winner: Mochi HealthMochi charges $99/month compounded semaglutide and $199/month compounded tirzepatide at every dose tier including max therapeutic dose. Eden's pricing model is all-inclusive but escalates with dose tier. For users on max-dose protocols, Mochi wins on titration economics.
BBB and accreditation posture
Winner: EdenBoth providers have imperfect BBB profiles (Eden Not Rated with the file open since April 2024; Mochi NOT Accredited with complaints concentrated on cancellation and refund). Neither is BBB-accredited, but Eden's profile does not have an associated state pharmacy enforcement record on the affiliated pharmacy, which is what matters here. Eden wins this row on the broader regulatory-posture comparison rather than BBB grades alone.
Operational scale and consumer reach
Winner: Mochi HealthMochi has the larger external review sample and higher operational scale by Trustpilot volume. Eden is smaller-scale but with a cleaner regulatory record. For users who weight consumer-scale signals (more reviews mean more data points), Mochi wins this row in isolation, even though the broader comparison routes most readers to Eden.
Rubric scores side-by-side
Same six dimensions we use on every provider profile, weighted to a single 0-5 score. Click through to either profile for the verification details behind each row.
Licensure 20% weight
Accreditation 20% weight
Transparency 20% weight
Product quality 15% weight
Pricing 15% weight
Customer service 10% weight
Pricing in plain terms
Mochi: $79/mo membership + $99/mo flat semaglutide or $199/mo flat tirzepatide at every dose ($178-$278/mo all-in). Eden: all-inclusive cash-pay program tiers, mid-range for the cohort with the vertical-integration premium baked in. Mochi tends to be cheaper, especially at higher doses, but the pricing gap is much smaller than the trust-signal gap. For users where trust signals matter at all, Eden's slightly higher monthly cost buys a meaningfully cleaner regulatory record.
Read the full profiles
This comparison summarizes the head-to-head call. The full provider profiles include verification items, regulatory history, public-review aggregation, and the signup walkthrough.